Insider transaction filing: MA — CRESCENT BIOPHARMA, INC.
Why now
Thesis: Crescent Biopharma insider filing is routine and lacks directional context.
Catalyst to watch: Full filing with transaction specifics.
Main risk: Insider selling could pressure shares.
Why it matters
Insider transaction filing is routine and lacks directional context without transaction specifics.
Details
CRESCENT BIOPHARMA, INC. filed SEC Form 4 on 2026-09-18.
Related assets & topics
Mastercard · MASources
- sec4 · sec.gov · 2026-09-18 00:00 UTC
- sec4 · sec.gov · 2026-09-18 00:00 UTC
- sec4 · sec.gov · 2026-09-18 00:00 UTC
- sec4 · sec.gov · 2026-09-18 00:00 UTC
- sec4 · sec.gov · 2026-09-18 00:00 UTC
- sec4 · sec.gov · 2026-09-18 00:00 UTC
- sec4 · sec.gov · 2026-09-18 00:00 UTC
- sec4 · sec.gov · 2026-09-18 00:00 UTC
- sec4 · sec.gov · 2026-09-18 00:00 UTC
- sec4 · sec.gov · 2026-09-18 00:00 UTC
- sec4 · sec.gov · 2026-09-18 00:00 UTC